Clinical Trials
125 trialsSonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
Canadian Cancer Trials Group
Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
SWOG Cancer Research Network
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Eastern Cooperative Oncology Group
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Children's Oncology Group
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
Canadian Cancer Trials Group
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Canadian Cancer Trials Group
Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma
Canadian Cancer Trials Group
CAPTUR
Canadian Cancer Trials Group
ACCESS
Center for International Blood and Marrow Transplant Research
ACCELERATE
Center for International Blood and Marrow Transplant Research
OPTIMIZE
Center for International Blood and Marrow Transplant Research
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
Canadian Cancer Trials Group
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
SWOG Cancer Research Network
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
SWOG Cancer Research Network
FINISH-HL
National Research Center for Hematology, Russia
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Center for International Blood and Marrow Transplant Research
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Cancer Trials Ireland
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
SWOG Cancer Research Network
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Eastern Cooperative Oncology Group
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
First Affiliated Hospital of Ningbo University
HiR+X
First Affiliated Hospital of Ningbo University
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
BURGUND
Polish Lymphoma Research Group
ACALLO
Polish Lymphoma Research Group
Bio-CHIC
Nordic Lymphoma Group
MOGAT
European Organisation for Research and Treatment of Cancer - EORTC
PARCT
European Organisation for Research and Treatment of Cancer - EORTC
ALTAMIRA
Nordic Lymphoma Group
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
REACH
European Organisation for Research and Treatment of Cancer - EORTC
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Center for International Blood and Marrow Transplant Research
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
OPERA-PLRG10
Polish Lymphoma Research Group
Bortezomib in Treating Patients With Mantle Cell Lymphoma
Canadian Cancer Trials Group
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Canadian Cancer Trials Group
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Canadian Cancer Trials Group
Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
Radiation Therapy Oncology Group
Methotrexate With or Without Cyclophosphamide in Treating Patients With Lymphocytic Leukemia
Eastern Cooperative Oncology Group
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
Eastern Cooperative Oncology Group
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
Eastern Cooperative Oncology Group
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Eastern Cooperative Oncology Group
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Eastern Cooperative Oncology Group
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
Eastern Cooperative Oncology Group
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Eastern Cooperative Oncology Group
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
Eastern Cooperative Oncology Group